Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care

被引:168
作者
Vijan, S
Hayward, RA
机构
[1] Univ Michigan, Dev Ctr Practice Management & Outcomes Res, Vet Affairs Hlth Serv Res & Dev, Ann Arbor, MI 48113 USA
[2] Michigan Diabet Res & Training Ctr, Ann Arbor, MI USA
关键词
D O I
10.7326/0003-4819-138-7-200304010-00018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypertension in patients with type 2 diabetes mellitus is a prevalent condition that leads to substantial morbidity and mortality. Purpose: To evaluate the goals and optimal agents for treatment of hypertension in type 2 diabetes. Data Sources: Review of the medical literature Study Selection: Randomized trials that evaluated the pharmacologic treatment of hypertension in patients with diabetes and reported microvascular and macrovascular outcomes. Data Extraction: Studies were identified by using the Cochrane Library, MEDLINE, meta-analyses, review articles, and expert recommendation. The searches of the Cochrane Library and MEDLINE were performed in May 2000 and updated in April 2002. Data were abstracted to standardized forms by a single reviewer and were confirmed by a second reviewer. Data Synthesis: Treatment of hypertension in type 2 diabetes provides dramatic benefit. Target diastolic blood pressures of less than 80 mm Hg appear optimal; systolic targets have not been as rigorously evaluated, but targets of 135 mm Hg or less are reasonable. Studies that compare drug classes do not suggest obviously superior agents. However, it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensin-converting enzyme (ACE) inhibitors may be the preferred first-line agents for treatment of hypertension in diabetes. beta-Blockers and calcium-channel blockers are more effective than placebo, but they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; however, study results are inconsistent in this regard. Conclusions: Treatment of hypertension in type 2 diabetes, with blood pressure goals of 135/80 mm Hg, provides dramatic benefits. Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may be the best first-line treatments, although other agents are usually necessary and goals may not be achieved even with three or four agents. Aggressive blood pressure control may be the most important factor in preventing adverse outcomes in patients with type 2 diabetes.
引用
收藏
页码:593 / 602
页数:10
相关论文
共 73 条
  • [21] Gerstein HC, 2000, LANCET, V355, P253
  • [22] Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study
    Hansson, L
    Hedner, T
    Lund-Johansen, P
    Kjeldsen, SE
    Lindholm, LH
    Syvertsen, JO
    Lanke, J
    de Faire, U
    Dahlöf, B
    Karlberg, BE
    [J]. LANCET, 2000, 356 (9227) : 359 - 365
  • [23] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616
  • [24] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [25] Black-white differences in risk of developing retinopathy among individuals with type 2 diabetes
    Harris, EL
    Sherman, SH
    Georgopoulos, A
    [J]. DIABETES CARE, 1999, 22 (05) : 779 - 783
  • [26] Harris M I, 1990, Clin Geriatr Med, V6, P703
  • [27] EPIDEMIOLOGIC CORRELATES OF NIDDM IN HISPANICS, WHITES, AND BLACKS IN THE UNITED-STATES POPULATION
    HARRIS, MI
    [J]. DIABETES CARE, 1991, 14 (07) : 639 - 648
  • [28] NONINSULIN-DEPENDENT DIABETES-MELLITUS IN BLACK AND WHITE AMERICANS
    HARRIS, MI
    [J]. DIABETES-METABOLISM REVIEWS, 1990, 6 (02): : 71 - 90
  • [29] Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults - The Third National Health and Nutrition Examination Survey, 1988-1994
    Harris, MI
    Flegal, KM
    Cowie, CC
    Eberhardt, MS
    Goldstein, DE
    Little, RR
    Wiedmeyer, HM
    Byrd-Holt, DD
    [J]. DIABETES CARE, 1998, 21 (04) : 518 - 524
  • [30] Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542